Internal Medicine, Nephrology · McAllen, TX
NPI
1376705244
Since 2008
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1901 S 1st St, Ste. 600
McAllen, TX, 78503
Phone (956) 631-6136
Groups this clinician bills Medicare through
Medicare paid, 2024
$121K
1,211 services
Medicare patients, 2024
336
Average age 71
Drug cost, 2024
$925K
1,780 prescriptions
Company payments, 2025
$1,358
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ricardo A Baltodano was code 99232 (hospital e&m - subsequent), 266 times for 120 patients. In total Ricardo A Baltodano billed 1,211 services in 16 codes, and Medicare paid $121K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-11-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 266 | 120 | $63.06 | $17K |
| 90960 ESRD Related Services (not dialysis) | Office | 200 | 51 | $274.26 | $55K |
| 99233 Hospital E&M - Subsequent | Facility | 163 | 115 | $94.72 | $15K |
| 99214 Office E&M - Established | Office | 113 | 77 | $95.41 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 90 | 72 | $13.52 | $1,217 |
| 90961 ESRD Related Services (not dialysis) | Office | 37 | 25 | $234.97 | $8,694 |
| 99213 Office E&M - Established | Office | 27 | 26 | $64.14 | $1,732 |
| 99204 Office E&M - New | Office | 18 | 18 | $120.22 | $2,164 |
| 99223 Hospital E&M - Initial | Facility | 15 | 15 | $120.52 | $1,808 |
By year: 2022 $169K for 1,375 services; 2023 $117K for 1,045 services; 2024 $121K for 1,211 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ricardo A Baltodano prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 213 prescriptions and refills. In total Ricardo A Baltodano wrote 1,780 Medicare prescriptions that cost $925K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 213 | 264 | 54 | $141K |
| Nifedipine Er Nifedipine | 173 | 292 | 48 | $3,501 |
| Veltassa Patiromer Calcium Sorbitex | 133 | 158 | 44 | $151K |
| Auryxia Ferric Citrate | 132 | 240 | 45 | $381K |
| Kerendia Finerenone | 112 | 114 | 22 | $71K |
| Sevelamer Carbonate Generic | 98 | 171 | 39 | $32K |
| Olmesartan Medoxomil Generic | 71 | 105 | 19 | $645 |
| Lisinopril Generic | 69 | 104 | 17 | $342 |
| Carvedilol Generic | 66 | 116 | 24 | $207 |
| Bumetanide Generic | 65 | 87 | 19 | $1,197 |
| Losartan Potassium Generic | 57 | 120 | 20 | $394 |
| Hydralazine Hcl Generic | 56 | 82 | 25 | $436 |
| Amlodipine Besylate Generic | 55 | 91 | 19 | $237 |
| Metoprolol Succinate Generic | 34 | 67 | 12 | $617 |
| Lokelma Sodium Zirconium Cyclosilicate | 32 | 49 | 11 | $38K |
Brand drugs: - claims; generic drugs: 1,084 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ricardo A Baltodano $1,358 ($1,358 in general payments such as food, travel and fees) from 11 companies. The largest payer was Vifor Pharma, Inc. with $507.
| Company | Payments | Amount |
|---|---|---|
| Vifor Pharma, Inc. | 38 | $507 |
| AstraZeneca Pharmaceuticals LP AZN | 14 | $373 |
| Amgen Inc. AMGN | 14 | $190 |
| Calliditas Therapeutics US Inc. | 4 | $83.8 |
| Apellis Pharmaceuticals, Inc. APLS | 2 | $63.51 |
| Fresenius USA Marketing, Inc. | 2 | $49.79 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $24.68 |
| Ardelyx, Inc. ARDX | 1 | $17.47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16.5 |
| Genzyme Corporation SNY | 1 | $16.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.